The FDA on Monday approved Wilserdly, also known as giredestrant, a new breast cancer medicine from Roche, clearing the way for a launch that the Swiss drugmaker has said could become its best-selling product ever.

The decision was one of the most closely watched regulatory milestones for Roche. It also strengthens the company’s position in breast cancer, where it has a long legacy through Genentech’s Herceptin but has more recently lost ground in oncology to rival pharmaceutical companies.

The approval specifically covers patients with HR-positive, HER2-negative advanced breast cancer whose tumors carry an ESR1 mutation, a sign that the cancer is developing resistance to standard treatments. In the evERA trial, giredestrant—an oral selective estrogen receptor degrader, or SERD—extended the time before patients’ tumors progressed.



Source link

Exit mobile version